Company Description
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma.
In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.
Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Timothy Lu |
Contact Details
Address: 2 Corporate Drive, First Floor South San Francisco, California 94080 United States | |
| Phone | 650 239 2030 |
| Website | sentibio.com |
Stock Details
| Ticker Symbol | SNTI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001854270 |
| CUSIP Number | 81726A100 |
| ISIN Number | US81726A2096 |
| Employer ID | 86-2437900 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Kanya Rajangam M.D., Ph.D. | President, Head of Research and Development and Chief Medical Officer |
| Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board and Independent Director |
| Dr. Wilson Wong Ph.D. | Scientific Co-Founder and Member of Scientific Advisory Board |
| Jay Cross | Chief Financial Officer |
| Faraz Siddiqui | Senior Vice President of Technical Operations |
| Robert H. Cutler J.D. | Senior Vice President and Head of Legal Affairs |
| Thomas P. Chung | Vice President of Strategic Finance and Corporate Development |
| Dee Olomajeye Dragon | Vice President of People and Culture Strategy & Head of Administrative Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 18, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | SCHEDULE 13G/A | Filing |